Press Enter to search · ESC to close

US Stocks

Eli Lilly shares rise 3% premarket after China’s NMPA approves oral GLP-1 weight-loss drug

Eli Lilly’s US-listed shares rose about 3% in premarket trading after China’s National Medical Products Administration approved the company’s oral GLP-1 weight-loss drug for marketing. The approval covers the oral formulation of Lilly’s GLP-1-based obesity treatment in China. The premarket move reflects investor reaction to the regulatory green light for the drug in the Chinese market.

Share

Related News

新云社 share card
Long-press image above → Save to Photos / Share
Pitch us Feedback